Back to Results

Sophia Genetics SA (SOPH)

Featured in Overvalued Stocks Small-Cap Stocks

Sophia Genetics SA is a healthcare technology company listed on NASDAQ as common stock. The company develops cloud-native software for the healthcare sector, centered on its SOPHiA DDM platform, which is designed to analyze multimodal data sets and generate diagnostic insights. Its software and related applications are used by hospitals, laboratories, and biopharmaceutical companies. Sophia Genetics serves these customers through a direct sales force as well as distributors and industry collaborators across Switzerland, France, Italy, the rest of Europe, North America, the United States, Latin America, and the Asia-Pacific region. Incorporated in 2011, the company is based in Rolle, Switzerland.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Upcoming Dividend Ex-Date Dividend Payment Date Upcoming Dividend Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
NASDAQ-SOPH
$4.56
-30.1% Downside
Overvalued
$9
37.9% Upside
Undervalued
Fair
—
—
—
0.0%
August 11, 2026
-6.8x
12.1x
6.8x
531.1 M
550.7 M
10.5%
76.2%
-12.1
—
51.5%
Valuation • Fair Value

Sophia Genetics SA (NASDAQ-SOPH) Fair Value by Valuation Model

Compare the primary fair value estimate for Sophia Genetics SA (NASDAQ-SOPH) with model-based valuation references such as DCF, Ben Graham, DDM, EPV and comparable-company valuation.

Primary Valuation Read

Fair Value

$4.56

Estimated downside of 30.1% versus the current market price.

Fair Value Confidence

Med

Confidence level for the primary fair value estimate.

DCF Fair Value

$4.70

Discounted cash flow valuation reference.

Ben Graham Formula Value

$0

Classic Ben Graham valuation formula reference.

DDM Fair Value

NM

Dividend discount model valuation reference.

EPV Fair Value

NM

Earnings power value estimate.

Comps Fair Value

$4.43

Comparable-company valuation reference.

Analyst Price Target

$9

Analysts imply upside of 37.9%.

How to read these valuation models

Use this section to compare the primary fair value estimate for Sophia Genetics SA (NASDAQ-SOPH) with several model-based valuation references. Different models can produce different outputs because each method relies on a different set of assumptions, so the primary fair value estimate should be read alongside the model spread rather than in isolation.

Profitability • Growth

Profitability & Growth for Sophia Genetics SA (NASDAQ-SOPH)

A compact read on revenue, forward revenue expectations, EBITDA and operating profitability trends.

Revenue

81.18 M

Current operating scale indicator.

Revenue Forecast

93.453 M

Forward revenue estimate.

EBITDA

-70.322 M

Current operating profitability reference.

EBITDA Forecast

-30.851 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Sophia Genetics SA (NASDAQ-SOPH) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Sophia Genetics SA (NASDAQ-SOPH)

Review financial health, earnings quality and balance-sheet risk through Piotroski, Beneish, Altman and cash conversion metrics.

Financial Health

Fair

Mixed or neutral financial-health read.

Piotroski Score

2

Weak quality score that deserves closer review.

Beneish M-Score

-3.61

No elevated caution signal from this screen.

Altman Z-Score

-12.1

Lower score that deserves closer risk review.

FCF / Net Income

51.5%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Sophia Genetics SA (NASDAQ-SOPH). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Sophia Genetics SA (NASDAQ-SOPH)

Track the next earnings date, ex-dividend date, dividend payment date, dividend yield and upcoming distribution details where available.

Next Earnings Date

August 11, 2026

Days to Earnings

21

Dividend Payment Date

Not available

Ex-Dividend Date

Not available

Dividend Yield

0.0%

Income yield reference.

Upcoming Dividend

Not available

Data is currently unavailable.

Payment Type

Not available

Data is currently unavailable.

Dividend Currency

Not available

Data is currently unavailable.

Payout Ratio

Not available

Data is currently unavailable.

How to read events and dividends

This section helps investors track time-sensitive items for Sophia Genetics SA (NASDAQ-SOPH), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Sophia Genetics SA (NASDAQ-SOPH) Stock Forecast & Technical Outlook

Review Sophia Genetics SA (NASDAQ-SOPH) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Buy

The 15-minute technical read for Sophia Genetics SA (NASDAQ-SOPH) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Buy

The 1-hour technical read for Sophia Genetics SA (NASDAQ-SOPH) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Buy

The daily technical read for Sophia Genetics SA (NASDAQ-SOPH) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Buy

The weekly technical read for Sophia Genetics SA (NASDAQ-SOPH) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Buy

The monthly technical read for Sophia Genetics SA (NASDAQ-SOPH) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Sophia Genetics SA (NASDAQ-SOPH)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, Sophia Genetics SA (NASDAQ-SOPH) has a Strong Buy consensus, with 5 buy, 0 hold and 0 sell recommendations in the current data set.

Buy 5
Hold 0
Sell 0
FAQ • Fast Investor Answers

Sophia Genetics SA (NASDAQ-SOPH) Stock FAQ

Quick answers about Sophia Genetics SA (NASDAQ-SOPH) stock, including fair value, valuation rating, analyst price target, dividends, earnings dates, market capitalization, financial health and other key stock analysis metrics.

Fair Value
$4.56
Estimated downside 30.1%
Valuation Rating
Overvalued
Estimated downside of 30.1%
Analyst Target
$9
Implied upside 37.9%
Financial Health
Fair
Current financial-health read

The current fair value estimate for Sophia Genetics SA (NASDAQ-SOPH) is $4.56. This implies an estimated downside of 30.1% versus the current market price.

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 30.1% versus the current market price.

The available analyst price target for Sophia Genetics SA (NASDAQ-SOPH) is $9. The analyst target implies estimated upside of 37.9%.

The current financial health read for Sophia Genetics SA (NASDAQ-SOPH) is Fair. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Sophia Genetics SA (NASDAQ-SOPH) is August 11, 2026.

Based on the current data, dividend yield is 0.0%.

The current P/E ratio listed for Sophia Genetics SA (NASDAQ-SOPH) is -6.8x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Sophia Genetics SA is 531.1 M.

The current enterprise value listed for Sophia Genetics SA is 550.7 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Sophia Genetics SA is NASDAQ-SOPH, and the stock is listed on NASDAQ.

Sophia Genetics SA (NASDAQ-SOPH) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Sophia Genetics SA is 10.5%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Sophia Genetics SA is 76.2%. Free float helps investors understand how much of the share base is available for public trading.

Similar Health Care Technology Stocks on NASDAQ View more

Waystar Holding Corp (WAY) Waystar Holding Corp (WAY)
Heartflow Inc (HTFL) Heartflow Inc (HTFL)
Schrodinger Inc (SDGR) Schrodinger Inc (SDGR)
Certara Inc (CERT) Certara Inc (CERT)
Goodrx Holdings Inc (GDRX) Goodrx Holdings Inc (GDRX)
HealthStream Inc (HSTM) HealthStream Inc (HSTM)
Trubridge Inc (TBRG) Trubridge Inc (TBRG)
Simulations Plus Inc (SLP) Simulations Plus Inc (SLP)
LifeMD Inc (LFMD) LifeMD Inc (LFMD)
LifeMD Inc Preferred Series A (LFMDP) LifeMD Inc Preferred Series A (LFMDP)
Health Catalyst Inc (HCAT) Health Catalyst Inc (HCAT)
OPTIMIZERx Corp (OPRX) OPTIMIZERx Corp (OPRX)
Definitive Healthcare Corp (DH) Definitive Healthcare Corp (DH)
CareCloud Inc (CCLD) CareCloud Inc (CCLD)
DarioHealth Corp (DRIO) DarioHealth Corp (DRIO)
Onemednet Corp (ONMD) Onemednet Corp (ONMD)
ITonic Holdings Ltd (ITOC) ITonic Holdings Ltd (ITOC)
Firefly Neuroscience Inc (AIFF) Firefly Neuroscience Inc (AIFF)
Scienture Holdings Inc (SCNX) Scienture Holdings Inc (SCNX)
BullFrog AI Holdings Inc Unit (BFRG) BullFrog AI Holdings Inc Unit (BFRG)
Aclarion Inc (ACON) Aclarion Inc (ACON)
Vsee Health Inc (VSEE) Vsee Health Inc (VSEE)
Healthcare Triangle Inc (HCTI) Healthcare Triangle Inc (HCTI)
ISpecimen Inc (ISPC) ISpecimen Inc (ISPC)